Published date: Aug 09 2022

Journal Title: Journal of Ophthalmic and Vision Research

Issue title: July–Sep 2022, Volume 17, Issue 3

Pages: 376 – 383

DOI: 10.18502/jovr.v17i3.11575

Saeed Karimidr.saeedkarimi@gmail.comOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Farhad ParviziDepartment of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Amir ArabiDepartment of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Toktam ShahrakiDepartment of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Sare SafiOphthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Purpose: To evaluate the therapeutic response of retinal vein occlusion (RVO) to intravitreal bevacizumab (IVB) with and without concomitant vitamin D supplementation.

Method: Seventy eyes of 68 patients with macular edema associated with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) received three monthly IVB injections. Patients with serum 25-hydroxyvitamin D (25(OH) D) higher than 30 ng/ml were considered as the sufficient group. Cases with serum 25(OH) D levels below 30 ng/ml were randomized into the treatment and control groups. The control group received 50,000 IU of oral vitamin D, weekly for two months. One month after the last IVB injection, best-corrected visual acuity (BCVA) and central macular thickness (CMT) were measured and compared with the preinjection values.

Results: While 43 eyes (61.4%) of 42 patients had BRVO, 27 eyes (38.6%) of 26 patients had CRVO. In BRVO patients, changes of CMT and BCVA were not significantly different between the sufficient, control, and treatment groups (P = 0.58 and 0.64, respectively). In the CRVO group, CMT reduction in the control group was significantly less than the sufficient and treatment groups (P = 0.048). In addition, improvement of BCVA in the control group was significantly less (P = 0.036) than the sufficient and treatment groups.

Conclusion: Oral vitamin D supplement therapy may improve anatomical and functional outcomes in patients with CRVO and vitamin D deficiency.

Keywords: 25-Hydroxyvitamin D, Bevacizumab, Insufficiency, Intravitreal, Macular Edema, Retinal Vein Occlusion

1. Oli A, Joshi D. Serum vitamin D levels in Indian patients with retinal venous occlusions. Saudi J Ophthalmol 2017;31:76–79.

2. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80:1689S– 1696S.

3. Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Invest 1987;79:1706–1712.

4. Akin F, Ayça B, Köse N, Duran M, Sari M, Uysal OK, et al. Serum vitamin D levels are independently associated with severity of coronary artery disease. J Investig Med 2012;60:869–873.

5. Epstein D, Kvanta A, Lindqvist PG, Vitamin D. Vitamin D deficiency in patients with central retinal vein occlusion: A case control study. Curr Eye Res 2017;42:448–451.

6. Talcott KE, Eliott D. Central retinal vein occlusion associated with severe vitamin D deficiency. Ophthalmic Surg Lasers Imaging Retina 2016;47:372–375.

7. Vatandost S, Jahani M, Afshari A, Amiri MR, Heidarimoghadam R, Mohammadi Y. Prevalence of vitamin D deficiency in Iran: A systematic review and meta-analysis. Nutr Health 2018;24:269–278.

8. Zittermann A, Schleithoff SS, Götting C, Dronow O, Fuchs U, Kuhn J, et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail 2008;10:321–327.

9. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003;88:327–331.

10. Snijder MB, Lips P, Seidell JC, Visser M, Deeg DJ, Dekker JM, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: A population-based study in older men and women. J Intern Med 2007;261:558–565.

11. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25- hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med 2008;168:1174–1180.

12. Targher G, Bertolini L, Padovani R, Zenari L, Scala L, Cigolini M, et al. Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol 2006;65:593–597.

13. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008;25:320–325.

14. Luo BA, Gao F, Qin LL. The association between vitamin D deficiency and diabetic retinopathy in type 2 diabetes: A meta-analysis of observational studies. Nutrients 2017;9:307.

15. Yin K, Agrawal DK. Vitamin D and inflammatory diseases. J Inflamm Res 2014;7:69–87.

16. Danik JS, Manson JE. Vitamin d and cardiovascular disease. Curr Treat Options Gastroenterol 2012;14:414– 424.

17. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: The Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726–732.

18. Karia N. Retinal vein occlusion: Pathophysiology and treatment options. Clin Ophthalmol 2010;4:809–816.

19. Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009;4:e8158.

20. Vieira MJ, Campos A, do Carmo A, Arruda H, Martins J, Sousa JP. Thrombophilic risk factors for retinal vein occlusion. Sci Rep 2019;9:18972.

21. Martins D, Meng YX, Tareen N, Artaza J, Lee JE, Farodolu C, et al. The effect of short term vitamin D supplementation on the inflammatory and oxidative mediators of arterial stiffness. Health 2014;6:1503–1511.